A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer.

Trial Profile

A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2012

At a glance

  • Drugs Tesetaxel (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Mar 2012 Planned number of patients changed from 27 to 54 as reported by M.D. Anderson Cancer Center record.
    • 16 Mar 2012 New source identified and integrated (2009-0995; M.D. Anderson Cancer Center).
    • 12 Mar 2012 Planned End Date changed from 1 Apr 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top